Courtney Csikesz, MD
Dermatology · Weymouth, MANPI 1760619902
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,433 of the $20,309 with a category attached, or 80.9%. It is spread thinly across 36 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $6,129, 3.3 times the $1,884 reported in 2019. Among dermatology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 788 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- AbbVie$4K
- LEO Pharma Inc.$2K
- Johnson & Johnson$1K
- Incyte Corporation$1K
- Novartis$1K
- plus $7K from 30 others
What the payments were for
- Speaking & faculty fees$3,45517%
- Food & beverage$16,43381%
- Education$4212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,309 in reported general payments places this provider in the 90th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $234,541 |
| Dupixent PenDupilumab | 36 | $136,199 |
| Taltz AutoinjectorIxekizumab | 14 | $104,561 |
| Ketoconazole | 102 | $2,075 |
| Clobetasol Propionate | 20 | $1,284 |
| Mometasone Furoate | 50 | $1,093 |
| Triamcinolone Acetonide | 72 | $1,067 |
| Fluocinonide | 24 | $1,015 |
| Doxycycline Hyclate | 26 | $897 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 16 | $497 |
| Clindamycin Phosphate | 11 | $460 |
| ValacyclovirValacyclovir Hcl | 24 | $376 |
| Hydrocortisone | 41 | $176 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Weymouth
- Susan DecosteWeymouth$18K
- John HarrisWorcester$15M
- Ethan LernerCharlestown$1.7M
- Michael KaminerChestnut Hill$1.1M
- Jeffrey SobellChestnut Hill$986K
- Erik DominguesFall River$736K
- Alexandra KimballBoston$680K
- Arash MostaghimiBoston$591K
- David GreensteinBeverly$540K
- Brian HiblerBoston$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.